• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

    20.90 +0.43 (+2.10%)
    Streaming Delayed Price Updated: 1:24 PM EDT, May 21, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Arcutis Biotherapeutics, Inc. - Common stock

    < Previous 1 2 3 4 5 Next >
    News headline image
    Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allure Magazine Honors Arcutis’ ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.